Korro Bio, Inc. Deferred Compensation Arrangement with Individual, Allocated Share-based Compensation Expense
Korro Bio, Inc. (KRRO) reported Deferred Compensation Arrangement with Individual, Allocated Share-based Compensation Expense of $179.00 thousand for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense · last filed 2023-11-02
- Korro Bio, Inc. deferred compensation arrangement with individual, allocated share-based compensation expense for the quarter ending 2023-09-30 was $179.00K, a 88.07% decline year-over-year.
- Korro Bio, Inc. deferred compensation arrangement with individual, allocated share-based compensation expense for the quarter ending 2023-06-30 was $169.00K.
- Korro Bio, Inc. deferred compensation arrangement with individual, allocated share-based compensation expense for the quarter ending 2023-03-31 was $170.00K.
- Korro Bio, Inc. deferred compensation arrangement with individual, allocated share-based compensation expense for the quarter ending 2022-12-31 was -$870.00K.
- Korro Bio, Inc. deferred compensation arrangement with individual, allocated share-based compensation expense for fiscal 2022 was $1.63M, a 34.93% decline from fiscal 2021.
- Korro Bio, Inc. deferred compensation arrangement with individual, allocated share-based compensation expense for fiscal 2021 was $2.50M.
| Period end | Deferred Compensation Arrangement with Individual, Allocated Share-based Compensation Expense | Deferred Compensation Arrangement with Individual, Allocated Share-based Compensation Expense 3 month | Deferred Compensation Arrangement with Individual, Allocated Share-based Compensation Expense 6 month | Deferred Compensation Arrangement with Individual, Allocated Share-based Compensation Expense 9 month | Deferred Compensation Arrangement with Individual, Allocated Share-based Compensation Expense 12 month |
|---|---|---|---|---|---|
| 2023-09-30 | $179.00K 10-Q · filed 2023-11-02 | $348.00K derived: sum of 2 quarters · filed 2023-11-02 | $518.00K 10-Q · filed 2023-11-02 | -$352.00K derived: sum of 4 quarters · filed 2023-11-02 | |
| 2023-06-30 | $169.00K 10-Q · filed 2023-08-10 | $339.00K 10-Q · filed 2023-08-10 | -$531.00K derived: sum of 3 quarters · filed 2023-08-10 | $969.00K derived: sum of 4 quarters · filed 2023-08-10 | |
| 2023-03-31 | $170.00K 10-Q · filed 2023-05-12 | -$700.00K derived: sum of 2 quarters · filed 2023-05-12 | $800.00K derived: sum of 3 quarters · filed 2023-05-12 | ||
| 2022-12-31 | -$870.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $630.00K derived: sum of 2 quarters · filed 2023-03-10 | $1.63M 10-K · filed 2023-03-10 | ||
| 2022-09-30 | $1.50M 10-Q · filed 2022-11-08 | $2.50M 10-Q · filed 2022-11-08 | |||
| 2022-08-17 | $2.50M 10-Q · filed 2023-11-02 | ||||
| 2021-12-31 | $2.50M 10-K · filed 2023-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |